Study Summary
The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesothelin (MSLN) and have lost HLA-A\*02 expression. The main questions this study aims to answer are: Phase 1: What is the recommended dose that is safe for patients Phase 2: Does the recommended dose kill solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: Enrollment and Apheresis in BASECAMP-1 (NCT04981119) Preconditioning Lymphodepletion (PCLD) Regimen Tmod CAR T cells at the assigned dose
Want to learn more about this trial?
Request More InfoInterventions
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Banner Health | Gilbert | Arizona | United States |
| UCSD Moores Cancer Center | La Jolla | California | United States |
| UCLA Medical Center | Los Angeles | California | United States |
| Stanford University | Stanford | California | United States |
| Mayo Clinic | Jacksonville | Florida | United States |
| Moffitt Cancer Center | Tampa | Florida | United States |
| Mayo Clinic Rochester | Rochester | Minnesota | United States |
| Washington University | St Louis | Missouri | United States |
| NYU Langone Medical Center | New York | New York | United States |
| The Ohio State University Comprehensive Cancer Center | Columbus | Ohio | United States |
| Vanderbilt University Medical Center | Nashville | Tennessee | United States |
| Fred Hutchinson Cancer Center | Seattle | Washington | United States |